Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice

Gastroenterology

Volumn 123, Issue 6, 2002, Pages 1912-1922

  Sugimoto, Ken ^a   Hanai, Hiroyuki ^a   Tozawa, Kotaro ^a   Aoshi, Taiki ^a   Uchijima, Masato ^a   Nagata, Toshi ^a   Koide, Yukio ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; T LYMPHOCYTE SUBPOPULATION;

EID: 0036892994     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.37050     Document Type: Article

References (46)

1. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-1367.
3. Strober W, Fuss IJ, Ehrhardt RO, Neurath M, Boirivant M, Ludviksson BR. Mucosal immunoregulation and inflammatory bowel disease: New insights from murine models of inflammation. Scand J Immunol 1998;48:453-458.
4. Boismenu R, Chen Y. Insights from mouse models of colitis. J Leukoc Biol 2000;67:267-278.
5. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-389.
6. Baldwin AS. The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 1996;14:649-683.
7. May MJ, Ghosh S. Signal transduction through NF-κB. Immunol Today 1998;19:80-88.
8. Neurath MF, Becker C, Barbulescu K. Role of NF-κB in immune and inflammatory responses in the gut. Gut 1998;43:856-860.
9. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-369.
10. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor κB inflammatory bowel disease. Gut 1998;42:477-484.
11. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
12. Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 [ELAM-1] or intercellular adhesion molecule-1 [ICAM-1]). Clin Exp Immunol 1999;117:462-468.
13. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-1174.
14. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 2000;119:1209-1218.
15. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95:3452-3457.
16. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-953.
17. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-290.
18. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-848.
19. Govindarajan VS. Turmeric-chemistry, technology, and quality. Crit Rev Food Sci Nutr 1980;12:199-301.
20. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 1996;26:111-120.
21. Singh AK, Sidhu GS, Deepa T, Maheshwari RK. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett 1996;107:109-115.
22. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci U S A 1991;88:5292-5296.
23. Xu YX, Pindolia KR, Janakiraman N, Noth CJ, Chapman RA, Gautam SC. Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp Hematol 1997;25:413-422.
24. Joe B, Rao UJ, Lokesh BR. Presence of an acidic glycoprotein in the serum of arthritic rats: Modulation by capsaicin and curcumin. Mol Cell Biochem 1997;169:125-134.
25. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995;94:79-83.
26. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995;270:24995-25000.
27. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κB activation. Biochem Pharmacol 1998;55:775-783.
28. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, Mackman N, Ziegler R, Nawroth PP. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 1997;77:772-782.
29. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB. Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 1999;163:3474-3483.
30. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-1290.
31. Yang F, de Villiers WJS, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced TNF production and lethality in a murine model. J Nutr 1998;128:2334-2340.
32. Yoshida A, Koide Y, Uchijima M, Yoshida TO. Dissection of strain difference in acquired protective immunity against Mycobacterium bovis Calmette-Gubrin Bacillus (BCG). J Immunol 1995;155:2057-2066.
33. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
34. Kang BY, Chung SW, Chung W, Im S, Hwang SY, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol 1999;384:191-195.
35. Kanai T, Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, Ishi H, Totsuka T, liyama R, Okamoto R, Ikeda M, Kurimoto M, Takeda K, Akira S, Hibi T. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001;121:875-888.
36. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-1270.
37. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-832.
38. Bille N, Larsen JC, Hansen EV, Wurtzen G. Subchronic oral toxicity of turmeric oleoresin in pigs. Food Chem Toxicol 1985;23:967-973.
39. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991;57:1-7.
40. Commandeur JN, Vermeulen NP. Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 1996;26:667-680.
41. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980;16:259-265.
42. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978;43:86-92.
43. 3H]curcumin. Toxicology 1981-1982;22:337-344.
44. Rao CV, Simi B, Reddy BS. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993;14:2219-2225.
45. Pereira MA, Grubbs CJ, Barnes LH, Li H, Olson GR, Eto I, Juliana M, Whitaker LM, Kelloff GJ, Steele VE, Lubet RA. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 1996;17:1305-1311.
46. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 1999;18:6013-6020.